of China assisted in or approved of the transportation of pill presses, fentanyl products, or fentanyl precursors to one or more Mexican drug cartels. (b) Reporting requirement If the determination of the Secretary of Defense under subsection (a) is an affirmative determination, the Secretary shall submit the determination to the Committees on Armed Services of the Senate and the House of Representatives. 1312. Analysis of certain biotechnology entities (a) In general Not later than 180 days after the date of the enactment of this Act, the Secretary of Defense shall conduct an analysis to determine if any biotechnology entity, or any subsidiary, parent, affiliate, or successor of such an entity, should be identified as a Chinese military company or a military-civil fusion contributor and included on the list maintained by the Department of Defense in accordance with section 1260H(b) of the National Defense Authorization Act for Fiscal Year 2021 ( 10 U.S.C. 113 note). (b) Biotechnology entity defined In this section, the term biotechnology entity means an entity that makes or offers a technology, good, or service that applies to or is enabled by life sciences innovation or product development for biological materials, including disease detection, genetic analysis, and related services. 1313. Studies on defense budget transparency of the People’s Republic of China and the United States (a) Studies required (1) Study of PRC budget Not later than 180 days after the date of the enactment of this Act, the Secretary of Defense shall submit to the congressional defense committees a study on the defense budget of the People’s Republic of China. (2) Comparative study on budgets Not later than 90 days after the date on which the study required by paragraph (1) is submitted, the Secretary of Defense shall submit to the congressional defense committees a comparative study on the defense budgets of the People’s Republic of China and the United States. (3) Objective The objective of the studies required by paragraphs (1) and